Clinical Trials Logo

Mucopolysaccharidosis IVA clinical trials

View clinical trials related to Mucopolysaccharidosis IVA.

Filter by:
  • Approved for marketing  
  • Page 1

NCT ID: NCT01858103 Approved for marketing - MPS IVA Clinical Trials

BMN 110 US Expanded Access Program

Start date: n/a
Phase: N/A
Study type: Expanded Access

The Expanded Access Program (EAP) is an open-label, multicenter program to: 1. Provide patients who have been diagnosed with Mucopolysaccharidosis IVA (MPS IVA) access to BMN 110 until commercial product is available 2. Collect additional information on the safety and tolerability of BMN 110 administration in patients with MPS IVA Patients enrolled in the EAP will receive 2.0 mg/kg intravenous infusions of BMN 110 every week during the program.